23209766|t|Postprandial apoE isoform and conformational changes associated with VLDL lipolysis products modulate monocyte inflammation.
23209766|a|OBJECTIVE: Postprandial hyperlipemia, characterized by increased circulating very low-density lipoproteins (VLDL) and circulating lipopolysaccharide (LPS), has been proposed as a mechanism of vascular injury. Our goal was to examine the interactions between postprandial lipoproteins, LPS, and apoE3 and apoE4 on monocyte activation. METHODS AND RESULTS: We showed that apoE3 complexed to phospholipid vesicles attenuates LPS-induced THP-1 monocyte cytokine expression, while apoE4 increases expression. ELISA revealed that apoE3 binds to LPS with higher affinity than apoE4. Electron paramagnetic resonance (EPR) spectroscopy of site-directed spin labels placed on specific amino acids of apoE3 showed that LPS interferes with conformational changes normally associated with lipid binding. Specifically, compared to apoE4, apoE bearing the E3-like R112 Ser mutation displays increased self association when exposed to LPS, consistent with a stronger apoE3-LPS interaction. Additionally, lipolysis of fasting VLDL from normal human donors attenuated LPS-induced TNFalpha secretion from monocytes to a greater extent than postprandial VLDL, an effect partially reversed by blocking apoE. This effect was reproduced using fasting VLDL lipolysis products from e3/e3 donors, but not from e4/e4 subjects, suggesting that apoE3 on fasting VLDL prevents LPS-induced inflammation more readily than apoE4. CONCLUSION: Postprandial apoE isoform and conformational changes associated with VLDL dramatically modulate vascular inflammation.
23209766	13	17	apoE	Gene	348
23209766	111	123	inflammation	Disease	MESH:D007249
23209766	136	161	Postprandial hyperlipemia	Disease	MESH:D006949
23209766	255	273	lipopolysaccharide	Chemical	MESH:D008070
23209766	275	278	LPS	Chemical	MESH:D008070
23209766	317	332	vascular injury	Disease	MESH:D057772
23209766	410	413	LPS	Chemical	MESH:D008070
23209766	419	424	apoE3	Gene	348
23209766	429	434	apoE4	Gene	348
23209766	495	500	apoE3	Gene	348
23209766	514	526	phospholipid	Chemical	MESH:D010743
23209766	547	550	LPS	Chemical	MESH:D008070
23209766	559	564	THP-1	CellLine	CVCL:0006
23209766	601	606	apoE4	Gene	348
23209766	649	654	apoE3	Gene	348
23209766	664	667	LPS	Chemical	MESH:D008070
23209766	694	699	apoE4	Gene	348
23209766	815	820	apoE3	Gene	348
23209766	833	836	LPS	Chemical	MESH:D008070
23209766	901	906	lipid	Chemical	MESH:D008055
23209766	942	947	apoE4	Gene	348
23209766	949	953	apoE	Gene	348
23209766	974	982	R112 Ser	ProteinMutation	tmVar:p|SUB|R|112|S;HGVS:p.R112S;VariantGroup:0;CorrespondingGene:348;CorrespondingSpecies:9606
23209766	1044	1047	LPS	Chemical	MESH:D008070
23209766	1076	1081	apoE3	Gene	348
23209766	1082	1085	LPS	Chemical	MESH:D008070
23209766	1151	1156	human	Species	9606
23209766	1175	1178	LPS	Chemical	MESH:D008070
23209766	1187	1195	TNFalpha	Gene	7124
23209766	1306	1311	apoE.	Gene	348
23209766	1441	1446	apoE3	Gene	348
23209766	1472	1475	LPS	Chemical	MESH:D008070
23209766	1484	1496	inflammation	Disease	MESH:D007249
23209766	1515	1520	apoE4	Gene	348
23209766	1547	1551	apoE	Gene	348
23209766	1630	1651	vascular inflammation	Disease	MESH:D007249
23209766	Association	MESH:D007249	348
23209766	Positive_Correlation	MESH:D008070	MESH:D006949
23209766	Association	MESH:D008070	348
23209766	Association	MESH:D008070	MESH:D057772
23209766	Positive_Correlation	MESH:D008070	7124
23209766	Positive_Correlation	MESH:D008070	MESH:D007249

